Skip to main content
SpringerLink
Log in

Renal Consequences of Prostaglandin Inhibition in Heart Failure

  • Chapter
  • First Online:
The Kidney in Heart Failure

  • 1092 Accesses

Abstract

Prostaglandins are products of intracellular arachidonate metabolism via the cyclooxygenase pathways. In the kidney, prostaglandins are modulators of afferent arteriole autoregulation. In states of diminished effective intravascular volume, vasodilatory prostaglandins reduce afferent arteriolar resistance, helping to maintain overall glomerular filtration. In subjects who have a low perfusion state, as in congestive heart failure (CHF), hepatorenal syndrome, and cirrhosis, impaired renal autoregulation occurs, predisposing to kidney injury. Adverse effects of prostaglandin inhibition include acute kidney injury, hyperkalemia, hypertension, and edema. Hypertension and edema occur because prostaglandins play an important role in renal regulation of salt and water balance. This review summarizes the renal consequences of using prostaglandin inhibitors in subjects who have CHF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol. 2007;3:637.

    Article  PubMed  Google Scholar 

  2. Krumholz HM, Chen Y. Correlates and impact on outcomes of worsening renal function in patients ≥65 years of age with heart failure. Am J Cardiol. 2000;85:1110–3.

    Article  PubMed  CAS  Google Scholar 

  3. Gottlieb SS, Abraham W. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136–41.

    Article  PubMed  Google Scholar 

  4. Smith GL, Vaccarino V. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13–25.

    Article  PubMed  CAS  Google Scholar 

  5. Cowie MR, Komajda M. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective study in heart failure (POSH). Eur Heart J. 2006;27:1216–22.

    Article  PubMed  Google Scholar 

  6. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268–74.

    Article  PubMed  Google Scholar 

  7. Logeart D, Tabet J. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol. 2008;127:228–32.

    Article  PubMed  Google Scholar 

  8. Metra M, Nodari S. Worsening renal function in patients hospitalized for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188–95.

    Article  PubMed  Google Scholar 

  9. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.

    Article  PubMed  Google Scholar 

  10. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in symptomatic and asymptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35(3):681–9.

    Article  PubMed  CAS  Google Scholar 

  11. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987;31(6):1402–15.

    Article  PubMed  CAS  Google Scholar 

  12. Cogan MG. Angiotensin II: a potent controller of sodium transport in the early proximal tubule. Hypertension. 1990;15(5):451–8.

    Article  PubMed  CAS  Google Scholar 

  13. Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders. 5th ed. New York: McGraw-Hill; 2001.

    Google Scholar 

  14. Hebert RL, Regnier L, Peterson LN. Rabbit cortical collecting ducts express a novel prostacyclin receptor. Am J Physiol. 1995;268:F145–54.

    PubMed  CAS  Google Scholar 

  15. Hebert RL, Jacobson HR, Breyer MD. Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest. 1991;87:1992–8.

    Article  PubMed  CAS  Google Scholar 

  16. Friss UG, Stubbe J, Uhrenholt TR, et al. Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. Am J Physiol Renal Physiol. 2005;289:F989–97.

    Article  Google Scholar 

  17. Chen L, Kim SM, Oppermann M, et al. Regulation of renin in mice with Cre recombinase mediated deletion of G protein Gsα in juxtaglomerular cells. Am J Physiol Renal Physiol. 2005;292:F27–37.

    Article  Google Scholar 

  18. Tang L, Loutzenhiser K, Loutzenhiser R. Biphasic actions of prostaglandin E2 on the renal afferent arteriole. Circ Res. 2000;86:663–70.

    Article  PubMed  CAS  Google Scholar 

  19. Purdy KE, Arendshorst WJ. EP1 and EP4 receptors mediate prostaglandin E2 actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol. 2000;279:F755–64.

    PubMed  CAS  Google Scholar 

  20. Imig JD, Breyer MD, Breyer RD. Contribution of prostaglandin EP2 receptors to renal microvascular reactivity in mice. Am J Physiol Renal Physiol. 2002;283:F415–22.

    PubMed  CAS  Google Scholar 

  21. Nasrallah R, Clark J, Hébert RL. Prostaglandins in the kidney: developments since Y2K. Clin Sci. 2007;113:297–311.

    Article  PubMed  CAS  Google Scholar 

  22. Oida H, Namba T, Sugimoto Y, et al. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol. 1995;116:2828–37.

    Article  PubMed  CAS  Google Scholar 

  23. Nasrallah R, Hébert RL. Prostacyclin signaling in the kidney: implications for health and disease. Am J Physiol Renal Physiol. 2005;289:235–46.

    Article  Google Scholar 

  24. Furci L, Fitzgerald DJ, Fitzgerald GA. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. J Pharmacol Exp Ther. 1991;258:74–81.

    PubMed  CAS  Google Scholar 

  25. Wilcox CS, Welch WJ, Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int. 1991;40:1090–7.

    Article  PubMed  CAS  Google Scholar 

  26. Paul BZ, Jin J, Kunapuli SP. Molecular mechanisms of thromboxane A2-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem. 1999;274(41):29108–13.

    Article  PubMed  CAS  Google Scholar 

  27. Okumura M, Imanishi M, Okamura M, et al. Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats. Life Sci. 2003;72:2695–705.

    Article  PubMed  CAS  Google Scholar 

  28. Vane JR, Botting RM. Thromb Res. 2003;110(5–6):255–6.

    Article  PubMed  CAS  Google Scholar 

  29. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308(14):800–5.

    Article  PubMed  CAS  Google Scholar 

  30. Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest. 1979;63:532–5.

    Article  PubMed  CAS  Google Scholar 

  31. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA. 1975;72:3073–6.

    Article  PubMed  CAS  Google Scholar 

  32. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24.

    Article  PubMed  CAS  Google Scholar 

  33. Harris RC. An update on cyclooxygenase-2 expression and metabolites in the kidney. Curr Opin Nephrol Hypertens. 2008;17:64–9.

    Article  PubMed  CAS  Google Scholar 

  34. Peti-Peterdi J, Komlosi P, Fuson AL, et al. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest. 2003;112:76–82.

    PubMed  CAS  Google Scholar 

  35. Qi Z, Cai H, Morrow JD, Breyer MD. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension. 2006;48:323–8.

    Article  PubMed  CAS  Google Scholar 

  36. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med. 2000;133(1):1–9.

    PubMed  CAS  Google Scholar 

  37. Laffi G, Daskalopoulos G, Kronborg I, et al. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology. 1986;90(1):182–7.

    PubMed  CAS  Google Scholar 

  38. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477–84.

    Article  PubMed  CAS  Google Scholar 

  39. Wong DG, Spence JD, Lamki L, et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by β-blockers and diuretics. Lancet. 1986;1(8488):997–1001.

    Article  PubMed  CAS  Google Scholar 

  40. Sahloul MZ, al-Kiek R, Ivanovich P, Mujais SK. Nonsteroidal anti-inflammatory drugs and antihypertensives. Cooperative malfeasance. Nephron. 1990;56:345–52.

    Article  PubMed  CAS  Google Scholar 

  41. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin–angiotensin system and hyponatremia. N Engl J Med. 1984;310(6):347–52.

    Article  PubMed  CAS  Google Scholar 

  42. Brater DC. Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide. J Pharmacol Exp Ther. 1979;210(3):386–90.

    PubMed  CAS  Google Scholar 

  43. Feenstra J, Heerdink ER, Grobbee DE. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch Intern Med. 2002;162:265–70.

    Article  PubMed  CAS  Google Scholar 

  44. Heerdink ER, Leufkens HG, Herings RMC, et al. NSAIDS associated with increased risk of CHF in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108–12.

    Article  PubMed  CAS  Google Scholar 

  45. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363(9423):1751–6.

    Article  PubMed  CAS  Google Scholar 

  46. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–9.

    Article  PubMed  CAS  Google Scholar 

  47. Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine. 1984;63:165–81.

    Article  PubMed  CAS  Google Scholar 

  48. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31:588–98.

    PubMed  CAS  Google Scholar 

  49. Kurata C, Uehara A, Sugi T, et al. Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors. Jpn Circ J. 1999;63:1002–3.

    Article  PubMed  CAS  Google Scholar 

  50. Jolobe OMP. Evaluation of renal function in elderly patients on ACE inhibitors. Postgrad Med J. 1999;75:275–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University of Maryland, School of Medicine, N3W143 Nephrology, UMMS, 22 S. Greene Street, Baltimore, MD, 21201, USA

    Eric M. Brown, Daniel J. Salzberg & Matthew R. Weir

Authors
  1. Eric M. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Salzberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew R. Weir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew R. Weir .

Editor information

Editors and Affiliations

  1. ASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC1027, Chicago, 60637, Illinois, USA

    George L. Bakris

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brown, E.M., Salzberg, D.J., Weir, M.R. (2012). Renal Consequences of Prostaglandin Inhibition in Heart Failure. In: Bakris, G. (eds) The Kidney in Heart Failure. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3694-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3694-2_9

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-3693-5

  • Online ISBN: 978-1-4614-3694-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation